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Abstract 
Liver transplant is the only curative treatment option for patients with end-stage liver failure, 
however there are few donor livers available for transplant. Tissue engineering of a human 
liver would potentially solve the problem of escalating donor shortages. A major challenge 
presents itself in the form of the hepatic extracellular matrix (ECM); a finely controlled in vivo 
niche which supports hepatocytes and plays a critical role in the development of liver disease. 
Polymers and decellularized tissues each provide some of the necessary biological cues for 
the hepatocytes, however, neither alone has proved sufficient. Equally, the ability to fine tune 
the microenvironment using bioactive molecules presents researchers with the opportunity to 
create personalised niches for hepatocytes, representing both normal and diseased 
phenotypes. This study combines cell derived ECM with a fibronectin vector and electrospun 
scaffolding techniques to produce a platform for creating customisable ECM 
microenvironments for hepatocytes (Abstract image). The resulting poly-L-lactic acid-
extracellular matrix (PLA-ECM) scaffolds were validated using HepG2 hepatocytes. 
 
As expected, statistically significant mechanical differences were observed between the 
synthetically derived ECM (SD-ECM) scaffolds and normal ECM (N-ECM) scaffolds, 
confirming that the ECM has been altered by the fibronectin producing vector. The PLA-ECM 
scaffolds maintained hepatocyte growth and function and influence the gene expression of 
key hepatic genes. Furthermore, immunohistochemistry showed SD and N-ECMs differed in 
ratios of Collagen I, Laminin and Fibronectin. 
Our results demonstrate that hybrid PLA-ECM scaffolds and the synthetic production of ECM 
provide a viable, translatable platform for customising microenvironments for hepatocytes. 
Abstract image. Methodology used to biofuctionalize electrospun scaffolds with 
synthetically derived ECM. 
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This technology offers a potential solution to current obstacles in regenerative medicine, 
disease modelling and whole organ tissue engineering. 
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Introduction 
In the US alone, as of August 20th 2017, the Organ Procurement and Transplantation Network 
(OPTN) estimates 14,158 patients are waiting for a donor liver. With a lack of viable new 
pharmaceuticals, liver transplant remains the sole treatment option for end-stage disease 
patients 1. Liver disease is an increasing burden on the health of the Western world, with both 
incidence and mortality increasing rapidly since 1970 2.   Demand for donor livers far outstrips 
supply, and the incidence of liver disease shows no signs of slowing down 3.  
Tissue engineers seek to solve this problem by engineering liver ‘organoids’; laboratory 
created organs which can function as a liver in vivo 4–7. The 3D environment exerts extensive 
influence on the behaviour and function of hepatocytes 6,8. With this in mind, tissue engineers 
employ scaffold manufacturing technologies to create structures which encompass key 
characteristics of the native 3D ECM 9–14. Several different methods of creating a scaffold are 
in use, and they can be made from a myriad of substances; both natural and synthetic 15, and 
enhanced with bio-decoration methods 8. There has been particular focus on decellularization, 
which provides an ECM bioscaffold with the 3D site-specific vasculature required for 
hepatocyte function upon their repopulation of the organ 16. Decellularized organs have been 
repopulated with hepatocytes and endothelial cells which subsequently survive and exhibit 
some level of function, clearly demonstrating the importance of the ECM in supporting 
hepatocyte survival and phenotype 17–21. However, decellularization requires a human or 
animal source of whole, undamaged organs and  while research is showing great promise, 
the field is fragmented and to date no scaffold has been created which allows hepatocytes to 
function as well as in vivo 22,23. 
Synthetic biology and genetic engineering are vital tools for tissue engineers and have been 
used to alter gene expression, enhance intracellular imaging and study fundamental 
processes in hepatocytes 24–26. Recently, synthetic biology tools have been successfully 
employed to direct both stem cell lineage and fate in 3D constructs 27,28, in the manipulation of 
biofilms for cell culture 29 and in the production of therapeutic proteins in in vivo systems 30,31 
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demonstrating the ability of synthetic biology techniques to manipulate 3D environments and 
thus their potential benefit to the field of tissue engineering.  Groundbreaking CRISPR 32–34 
and minicircle vector 35–37  technologies have made the idea of therapeutic gene editing in 
humans a viable reality, however concerns exist regarding the safety and subsequently, the 
translatability of such tools with regards to patient treatment. Heavily publicised and tragic 
events such as the 1999 death of 18 year old Jesse Gelsinger 38 and the 2002 clinical trial in 
which four children developed leukaemia following gene therapy for their Severe Combined 
Immune Deficiency disease 39 have led to obvious worries regarding the safety of gene 
therapies. The inflammatory and immune modulating effects of damage-associated molecular 
patterns (DAMPs) such as foreign DNA fragments 40 are well documented, however clinical 
use of decellularized ECM in exogenic and allogenic form has demonstrated great promise, 
giving no immune response and showing regenerative potential. This paves the way for using 
synthetic biology to tissue engineer the ideal ECM environment. The ideal ECM would utilise 
synthetic biology and genetic technologies to their utmost, considerable, potential but remove 
any risk from the tools used; such as the genetically modified cells themselves. 
Table 1; Advantages of a combinatorial approach to tissue engineering of liver environments. 
Polymer 
scaffolds 
Decellularized 
tissues 
Vector  
technology 
Combinatorial 
approach 
✓ 
 
Reproducible 
 
✓ 
Provides 
biochemical 
cues of ECM 
✓ 
Customizable 
protein profile ✓ 
 
Mechanically & 
proteomically 
customizable  
 
✓ 
Mechanically 
customizable ✓ 
Vasculature 
exists within 
tissue 
✓ 
Rapid 
production of 
desired 
proteins 
✓ 
 
Cell lines used - 
donors avoided 
 
 
Does not 
provide 
complex 
biochemical 
cues of ECM 
 
 Limited donors & donor safety  
Vector safety 
concerns ✓ 
 
Vectors removed - 
safety concerns 
abated 
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With the potential of synthetic biology for manipulation of protein production in mind, we set 
out to address this problem; developing a novel bio-active hybrid scaffold which possesses 
the potential for customizatioon of the ECM microenvironment. To date, no bioengineers have 
combined the promising fields of scaffold manufacture, decellularized tissue and synthetic 
biology. Here we report the first use of a sacrificial, transfected cell line to bio-functionalise an 
electrospun polymer scaffold for liver tissue engineering. We have successfully decellularized 
the bio-functionalised scaffold, and validated the platform using cells representative of the 
liver, HepG2s. 
Materials and Methods 
Electrospinning 
A 10% wt/vol solution of poly-L-lactic acid (Goodman) and hexafluoroisopropanol (Manchester 
Organics) was dissolved overnight at room temperature with agitation. Solutions were placed 
into a 10ml syringe and pumped using syringe pump EP-H11 (Harvard Apparatus) into the 
EC-DIG electrospinning system (IME technologies) via a 27G bore needle under the following 
parameters;  
Table 2; Electrospinning parameters 
Volume per 
hour 
Total 
volume 
Mandrel:needle 
distance 
Positive 
charge 
Negative 
charge 
Mandrel 
rotation 
Needle 
movement 
0.5ml 10ml 14 cm 16kV -3kV 250rpm 100mm/s 
 
The mandrel was coated in non-stick aluminium foil for collecting the electrospun fibres. The 
sheets of electrospun fibres were allowed to dry overnight in a fume hood when the 
electrospinning session was completed. The average fibre size was 1.48µm as calculated by 
ImageJ plugin ‘DiameterJ’ 41. 
Scaffold Preparation 
10mm discs of scaffold were cut from the dry fibre sheet. The scaffolds were soaked in 70% 
isopropyl alcohol for 10 minutes, rinsed three times in phosphate buffered saline for 15 
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minutes each and allowed to dry completely at room temperature. Scaffolds were placed into 
an antibiotic/antimycotic treatment solution of Dulbeccos Minimal Essential Media 
supplemented with 100U/ml penicillin, 100µg/ml streptomycin, 0.25µg/ml Fungizone® 
(amphotericin B) Anti-Anti solution (Gibco) for 1 hour. 
Initial Layer Cell Seeding and Culture 
Scaffolds were removed from the antibiotic/antimycotic treatment solution and rinsed three 
times for 15 minutes each in complete media; Dulbeccos Minimal Essential Media 
supplemented with 10% foetal bovine serum, 2mM L-glutamine, 100U/ml penicillin and 
100µg/ml streptomycin (Gibco). They were then placed into a fresh 48 well tissue culture plate. 
5637 human urinary bladder epithelials (ATCC) were cultured and expanded as per supplier 
recommendations, using the media described above. Cells for scaffold seeding were 
trypsinized using 0.25% Trypsin-EDTA (Gibco) from tissue culture flasks and counted using 
the trypan blue exclusion method. 1 x 105 cells at passage 23 were suspended in 100µl of 
complete media and seeded directly on to the scaffolds. The cells were allowed to incubate in 
this small volume on the scaffolds for 2 hours, before an additional 400µl of complete media 
was added.  
Media was changed after 24 hours using standard methods and subsequently changed every 
48 hours. Controls were scaffold only, i.e. not seeded with an initial cell layer and a ‘normal’ 
initial layer i.e. untransfected cells. Initial layers of cells were cultured for 7 days at 37ºC and 
5% CO2 in a humidified incubator. 
Fibronectin Vector 
Vectors were obtained from the DNASU plasmid repository. In brief, the human fibronectin 
gene (FN1) was placed into a retroviral expression vector, PJ1520. The insert sequence was 
verified by sequence analysis and restriction enzyme digest by DNASU. The vector was 
obtained in DH5-alpha T1 phage resistance Escheria coli glycerol stock. We cultured the E. 
coli under selective conditions; 100µg/ml ampicillin, 34µg/ml chloramphenicol and 7%wt/vol 
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sucrose in LB media. Plasmid extractions were performed using Cambridge Bioscience’s 
Zyppy™ plasmid extraction kit following manufacturer’s methods. 
Transfections 
Transfections were performed using Invitrogen Lipofectamine 3000®. Following titration 
experiments, a concentration of 1µg plasmid DNA and 0.75µL lipofectamine reagent per 
scaffold was chosen. The initial layer of 5637 epithelials was cultured on the scaffolds under 
standard conditions for 7 days. Transfection was performed on the 7th day. Scaffold-cell 
constructs were then placed into selective media containing 150µg/ml puromycin. The cell-
scaffold constructs were cultured under selection for a further 7 days to allow production of 
the vector derived fibronectin before being decellularized.  
Decellularization  
Decellularization was performed under sterile conditions at room temperature (19 - 22ºC) and 
with agitation. Scaffolds were placed into 50ml falcon tubes and placed on a rotator at 20RPM. 
Scaffolds were washed with phosphate buffered saline (PBS) for 15 minutes and then rinsed 
in 10mM tris buffered saline (TBS) for 15 minutes.  
The scaffolds were submerged in a 0.1% vol/vol Triton X-100 (Sigma-Aldrich) 1.5M potassium 
chloride (Acros Organics) 50mM TBS for 4 hours. They were rinsed for 15 minutes in 10mM 
TBS before being submerged in fresh 10mM TBS overnight. 
Scaffolds were given a final rinse in 10mM TBS for 15 minutes before being incubated in 
complete media for 15 minutes and then transferred to new 48 well plates for seeding. 
Functional layer Cell Seeding and Culture 
HepG2 cells were trypsinized using standard methods from tissue culture flasks and counted 
using the trypan blue exclusion method. 1 x 105 cells at passage 17 were suspended in 100µl 
of complete media and seeded directly on to the scaffolds. The cells were allowed to incubate 
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in this small volume on the scaffolds for 2 hours, before an additional 400µl of complete media 
was added. 
Media was changed after 24 hours and changed every 48 hours after the initial 24 hour 
adherence and recovery period. This functional layer (FL) of cells was cultured using standard 
methods for either 3 or 5 days at 37ºC and 5% CO2 in a humidified incubator. 
Live/Dead® Viability/Cytotoxicity assay 
To determine cellular viability, cell/scaffold constructs were incubated with 10µm calcein and 
2µm ethidium ho-modimer-1 (Ethd-1) for 30 minutes as part of the two colour live/dead assay 
(Molecular Probes). Calcein is actively converted to calcein-AM in living cells, which then 
appear green when excited during fluorescence microscopy. Ethd-1 only accumulates in dead 
cells, which subsequently appear red. The method allows differentiation between dead and 
viable cells. The scaffolds were rinsed three times in CaCl2/MgCl2 free PBS to remove excess 
dye and placed onto a standard microscope slide with a 25mm glass coverslip (VWR). All 
images were captured using a Zeiss Axio Imager fluorescent microscope (COIL, University of 
Edinburgh) at 40x magnification and post processed using ImageJ. 
CellTiter-Blue® Cell viability assay 
The assay was performed according to manufacturer’s instruction (Promega). For each 
condition group, n = 5. Importantly, cell/scaffolds constructs were moved into fresh 48 well 
plates to prevent reading activity from tissue culture plastic bound cells. Measurements were 
read in a Modulus™ II microplate reader at an excitation wavelength of 525 nm and emission 
wavelength of 580-640 nm and reported as fluorescence.  
Albumin quantification 
A bromocresol green (BCG) albumin assay (Sigma) was used to quantify serum albumin 
produced by the HepG2 functional cell layer over 24 hours at 3 and 5 day timepoints. The 
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assay was performed according to manufacturer’s instructions and results read at an 
absorbance of 620 nm in a Modulus™ II microplate reader. 
Picogreen® DNA quantification 
The Quant-IT™ Picogreen® dsDNA assay kit (Life Technologies™) was employed to establish 
the efficiency of the decellularization method in removing cellular material and to estimate cell 
number on the cell/scaffold constructs. The assay was performed according to manufacturer 
instructions. In brief, constructs (n = 5) were digested in a solution of CaCl2 and MgCl2 free 
PBS (Sigma),  containing  2.5  U/ml papain  extract  (Sigma)  5  mM cysteine-HCl  (Sigma)  
and  5 mM EDTA  (Sigma)  and incubated for 48 hours at 60°C. Picogreen solution was added 
to the digests and fluorescent intensity measurements read in a Modulus™ II microplate 
reader at an excitation wavelength of 480 nm and emission wavelength of 510-570 nm. A 
standard λ dsDNA curve of graded known concentrations was used to calibrate fluorescence 
intensity vs dsDNA concentration. 
Sectioning and staining 
The samples were rinsed three times in PBS (Gibco) for 15 minutes each, then fixed in 4% 
v/v formalin buffered in saline for 15 minutes at room temperature. After rinsing with fresh 
PBS, constructs were embedded in low melting temperature polyester wax (Electron 
Microscopy Supplies) using methods adapted from Steele et al. (2014). In brief, samples are 
dehydrated through 70-100% ethanol, then incubated in 50:50 ethanol:wax overnight at 45ºC 
overnight with agitation. The samples were moved into 100% wax for 3 hours at 45ºC and 
then fresh 100% wax for 1 hour at 45ºC. Samples were embedded and allowed 72 hours to 
fully cure before sectioning. Immunohistochemical staining was undertaken using antibodies 
for Collagen I (Stratech), Laminin (Stratech) and Fibronectin (Sigma).  All images were 
captured using a Zeiss Axio Imager system (Centre Optical Instrumentation Laboratory, 
University of Edinburgh) at 40x magnification and post processed using ImageJ. 
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Scanning Electron Microscopy 
SEM was used to characterise the scaffold architecture. Samples were rinsed three times in 
PBS for 15 minutes each, then fixed in 2.5% v/v glutaraldehyde (Fisher Scientific) in 0.1M 
phosphate buffer (PB) (pH 7.4) at 4ºC overnight. They were then rinsed three times in 0.1M 
PB before being post-fixed in 1% v/v osmium tetroxide (Electron Microscopy Supplies)   
buffered with 0.1M PB. Samples were again rinsed three times in 0.1M PB and dehydrated 
through an ethanol gradient (30-100%). They were dried by placing them in 
hexamethyldisilazane (HDMS, Sigma) which was allowed to evaporate off at room 
temperature overnight. We mounted the samples onto SEM chucks using double sided carbon 
tape and coated them with a thin layer of gold and palladium alloy (Polaron Sputtercoater). 
All images were captured at 5 kV using a Hitach S-4700 SEM (BioSEM, University of 
Edinburgh). 
Mechanical Testing 
Nanoindentation experiments were undertaken to establish the dynamic properties of 
scaffolds and decellularized ECM/scaffold constructs using the Keysight/Agilent 5200 nano 
indenter testing system. 
Scaffolds and constructs were subject to indentation by a DCM II actuator flat-ended cylindrical 
punch (D = 100µm) using a max load of 1g-f. All nanoindentation experiments were carried 
out on fresh, hydrated (suspended in PBS), unfixed samples in a stainless steel well chuck. A 
total of 36 indentations were carried out on each sample, 50nm apart. Indent sites were 
selected using the high precision X-Y stage within the testing system (Agilent). Poissons ratio 
was assumed to be 0.5 for each sample 42,43. Allowable drift rate was 0.1nm/s. A NanoSuite 
(Keysight Technologies) test method “G-Series DCM CSM Flat Punch Complex Modulus” was 
used for all testing 44,45. 
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Gene Expression analysis 
RNA was extracted from constructs using standard Trizol (Fisher Scientific) methods and 
purified using Qiagen’s RNeasy spin column system. cDNA was synthesised using the 
Promega’s ImProm-II™ Reverse Transcription System. 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the 
LightCycler® 480 Instrument II (Roche Life Science) and Sensifast™ SYBR® High-ROX 
(Bioline) system. Results were normalized to HepG2s of the same passage number grown on 
tissue culture plastic and compared to the housekeeping gene Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH). Analysis was performed using the 2–[delta][delta] Ct method 46,47, 
n = 5. Albumin (Alb), Cytochrome P450 Family 1 Subfamily A Polypeptide 1 (Cyp1A1), 
Cytochrome P450 Family 1 Subfamily A Polypeptide 2 (Cyp1A2), Cytochrome P450 Family 3 
Subfamily A Polypeptide 4 (Cyp3A4), Collagen Type I alpha 1 (Col1A1), Collagen Type 4 
alpha 1 (Col4A1) and Fibronectin Type 1 (FN1) were investigated, forward and reverse 
primers (Sigma) are detailed in Supplementary Table 1.  
 
Statistical Analysis 
One-way ANOVAs with Fishers, Games-Howell and Tukey 48–50 post-hoc testing were 
performed using Minitab 17 Statistical Software and graphs generated using Origin software 
(OriginLab, Northampton, MA). Error bars indicate standard deviation. A minimum of n = 3 
and max of n = 6 was used for all analysis. 
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Results  
Cell attachment and survival on scaffolds 
When compared to normal ECM derived 
from untransfected cells (N-ECM) and the 
scaffold alone (SO), a lower number of 
HepG2s adhered to the synthetically 
derived vector driven (SD-ECM) scaffold-
ECM constructs (Fig. 1). According to the 
CellTiter-Blue® results (Fig. 1A), the SD 
ECM layer maintained the growth of the 
HepG2s between days 3 and 5.  However, 
this result is not concurrent with the 
Picogreen® DNA quantitation (Fig. 1B). 
This is most likely due to different data 
extraction methods and validation 
methods in the Picogreen and CellTiter-
Blue assays. Both assays possess depth 
dependencies with regards to their 
efficiency and effectiveness in extracting 
data from fibrous scaffold constructs. 
Additionally, the assays were validated 
using 2D monolayer cell cultures. This 
would explain high standard deviations in the Picogreen® DNA quantitation dataset and slight 
different trends observed between the assays. These finding are corroborated by our recent 
published work of cells on electrospun scaffolds 14.  Live/Dead® Viability/Cytotoxicity images 
(Fig. 2) demonstrate the metabolic viability of the functional HepG2 cell layer (FL), and that at 
day 5 the cells appear to be confluent and living, with low levels of cell death in each condition. 
Figure 1. Cell titre blue assay indicating 
metabolic activity (A) and DNA quantitation of 
the functional layer (B). One way ANOVA with 
Games Howell post hoc testing, ** = p value 
<0.01. 
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 Mechanical characterisation of scaffolds 
Reassuringly, both storage (G’) and loss (G”) 
modulus demonstrate significant differences 
between the three conditions (Fig. 3). Fibronectin is 
known to influence both the mechanical profile of the 
ECM 51,52 and influence the maintenance and 
structure of other vital ECM proteins, such as 
collagen 53. Equally, cells are known to respond to 
the mechanical and topographical influence a 
scaffold exerts 54.  
Testing was performed at frequencies experienced 
by the human liver in vivo 55. Storage modulus (G’) 
ranged from 22.92±9.14 to 12.29±0.14 MPa and 
loss modulus (G’’) from 2.45±0.93 to 0.15±0.02 MPa 
at the frequencies detailed in supplementary tables 
2 and 3.  
 
 
 
Figure 2. Live Dead imaging demonstrating the 
living functional layer present at each time 
point, with minimal cell death. 
Figure 3. Significant mechanical differences 
were observed between all scaffold conditions. 
One way ANOVA with Games Howell post hoc 
testing, ** = p value <0.01. 
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Biochemical characterisation of the hybrid polymer-ECM scaffolds 
Differences in the biochemical profile of 
the different ECMs were demonstrated by 
immunohistochemistry performed on 
decellularized hybrid scaffold sections 
(Fig. 4). Hepatic cells are very responsive 
to extracellular matrix proteins; particularly 
Collagen I, Laminin and Fibronectin 56–58. 
Fibronectin is ubiquitous in healthy liver 
59,60, and antibody staining reveals altered 
levels of fibronectin in the synthetically 
derived ECM, as expected due to the 
introduction of the fibronectin vector (Fig. 
4H).  ECM proteins do not exist in 
isolation, and fibronectin is known to 
influence the generation and laydown of other ECM proteins including collagen I and laminin 
53,61, as evidenced in Fig. 4G and 4I when compared to N-ECM. The N-ECM is collagen I rich 
(Fig. 4D) with some fibronectin and laminin also present (Fig. 4E & 4F). Of note is that the SD-
ECM appears to be concentrated on the outer layers of the electrospun scaffold. This could 
be due to the transfected cells being in fewer number than those which were not transfected 
(N-ECM), so they did not penetrate the scaffold to the same extent.  
Gene expression of HepG2s in response to hybrid polymer-ECM scaffolds 
Genes associated with both liver function and ECM production were assayed for gene 
expression (Fig. 5). Albumin expression, a marker of appropriate liver cell differentiation and 
function, appears upregulated between day 3 and day 5 in each condition, confirming 
appropriate development of the cells. At day 5, expression is significantly upregulated in 
comparison to HepG2s grown on tissue culture plastic (TCP) on the SD-ECM constructs; with 
Figure 4. IHC staining showing the retention of 
major liver ECM proteins Collagen I (D, G), 
Fibronectin (E, H) and Laminin (F, I) following 
decellularization. Additionally, SO condition 
shows no positive staining as expected (A, B, 
C). 
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the highest levels of expression observed in SO and SD-ECM conditions. Additionally, albumin 
mRNA expression is downregulated in comparison to TCP at day 3 in all conditions (Fig. 5A). 
Cytochrome P450s (Cyp) are a family of enzymes involved in metabolism of xenobiotics and 
toxic compounds in the liver 62–64. Cyp1A1 mRNA expression is significantly altered in 
comparison to TCP (Fig. 5B); upregulated at day 3 and downregulated at day 5. Cyp1A2 
mRNA expression is consistently significantly downregulated in all but one condition; day 3 N-
ECM (Fig. 5C). Cyp3A4 mRNA expression is upregulated in every condition, with a significant 
upregulation observed in response to SD-ECM (Fig. 5D). 
In addition, we assayed for three ECM genes important for normal liver composition 59,65; 
Fibronectin (Fig. 5E), Collagen I (Fig. 5F) and Collagen IV (Fig. 5G). Considering the plastic 
nature of ECM, these genes are of 
interest with regards to ongoing 
modification of the tissue 
microenvironment despite hepatocytes 
not being the main producers of ECM 
proteins in the liver 59,66.  
Collagen I is consistently upregulated, 
with significant upregulation observed at 
day 5 on SD-ECM. Equally, Fibronectin 
mRNA expression is significantly 
upregulated on day 5 SD-ECM 
constructs, though downregulated at day 
3 on SO and N-ECM constructs. Collagen 
IV mRNA expression is consistently 
upregulated in each condition, with 
significant changes observed in all but day 
3 N-ECM and SD-ECM. While such 
Figure 5. Q-PCR results showing significant 
changes in expression of major liver genes 
when compared to TCP, Albumin (A), CYP1A1 
(B), CYP1A2 (C), CYP3A4 (D) an ECM genes 
Col 1A1 (E), Col 4A1 (F) and Fibronectin (G) 
between the hybrid scaffolds and tissue culture 
plastic. (A, C, D, E, F, G) = One way ANOVA 
with Games Howell post hoc testing, * = p 
value <0.05. (B) = One way ANOVA with Tukey 
post hoc testing, * = p value <0.05. 
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alterations in gene expression are promising, we refrain from further assumption regarding 
cell response without further proteomic and functional analyses. 
Albumin production 
Albumin levels are indicative of 
hepatocyte health and response to the 
microenvironment 57. Each condition 
results in differing levels of albumin 
production, with significant differences in 
protein levels observed between SO and 
SD-ECM at both 3 days and 5 days (Fig. 
6), indicating that the N-ECM encouraged 
albumin production more than SD-ECM.  
Confirmation of decellularization 
Decellularization was confirmed using 
Picogreen® DNA quantitation (Fig. 7G) 
and histological staining (Fig. 7A-F). A tenfold reduction in DNA combined with visual 
confirmation of an absence of DAPI nuclear staining and Phalloidin-514 actin staining on 
Figure 6. Albumin production between 
conditions, showing significant changes 
between SO and SD-ECM conditions at both 
time points. One way ANOVA with Games 
Howell post hoc testing, * = p value <0.05. ** 
= p value <0.01. 
Figure 7. Effectively decellularized constructs, with minimum remnant DNA detected by 
IHC (E,F) or picogreen (G). Scaffolds pre-decellularization shown in (A), (B) and (C). One 
way ANOVA with Games Howell post hoc testing, ** = p value <0.05. Scaffold only (A, D), 
N-ECM (B,E) and SD-ECM (C, F) 
 
Page 17 of 26 AUTHOR SUBMITTED MANUSCRIPT - BPEX-100928.R2
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 Ac
ce
pte
d M
an
us
cri
pt
decellularized constructs, plus the presence of fibronectin antibody staining on both the N-
ECM and SD-ECM decellularized constructs (Fig. 7E&F) provides evidence of efficient 
decellularization methods, and that synthetically derived fibronectin is present on the hybrid 
scaffolds.  
Discussion  
The extracellular matrix provides a microenvironment for cells which is not yet fully 
understood, nor replicable by existing manufacturing methods 16,67–69. By manipulating human 
cells to produce a customizable blend of ECM components, and combining this with replicable 
electrospun scaffolds and decellularization methods we overcome the shortage of donor 
derived ECM bioscaffolds and the issues regarding animal-sourced biomaterials 16,70. 
Additionally, this platform has the potential to be used to model not only ‘healthy’ ECM 
microenvironments, but also those of disease and developing states. 
By using fibrous electrospun scaffolds we mimic the morphology of healthy fibrillary collagen 
10,11,71,72. PLA was used to fabricate the scaffolds, chosen for its compatibility with hepatocytes 
56 and its use in multiple types of medical device due to its predictable biodegradation rate and 
mechanical properties 73,74.  
Fibronectin was chosen as our protein to synthetically overexpress due to its vital role in the 
liver 51,75 and its interaction with other ECM components such as collagen and laminin 52,53. 
Fibronectin is a large dimeric adhesive glycoprotein which exists in both cellular and plasma 
forms, with roles in regenerating tissues, embryonic development and regulation of cell 
behaviours such as adhesion and migration 76. The role of fibronectin in the liver is still unclear, 
with inhibition of fibronectin production or deposition improving fibrosis outcomes 77,78. 
However its vital role in the hepatic ECM is demonstrated by mutant mice who were 
specifically null in only the liver for both plasma and cellular fibronectin. The fibronectin-null 
livers not only develop highly disorganized/diffuse collagenous ECM networks, but when 
fibrogenesis was induced the null livers experienced more extensive fibrosis; thought to be 
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due to fibronectins role in regulating TGF-β1 bioavailability 75. Additionally, homozygous 
fibronectin null mutants display early embryonic lethality, while heterozygotes (with 50% of the 
normal plasma fibronectin levels) appear normal; suggesting a dose dependent role for 
fibronectin in development 79. 
As an initial assessment of these novel hybrid scaffolds we investigated the attachment and 
function of a commonly used liver cell line, HepG2s, when cultured on the synthetically derived 
hybrid scaffolds versus a wild type ‘normal’ hybrid scaffold and the scaffold alone. The HepG2 
cell line was derived from the hepatocarcinoma of a 15 year old Caucasian male. They are 
often used because they are virus free, possess liver specific functions such as ammonia 
metabolism and albumin synthesis and secrete some growth factors 80.  We analysed cell 
attachment and viability, albumin production and gene expression of both liver function genes 
and ECM genes at 3 and 5 day time points. Additionally, we validated our decellularization 
method and performed both immunohistochemical and raman spectrum analyses (data not 
shown) of the hybrid scaffold-ECM constructs upon which the HepG2s were seeded.  
Our results indicate not only that synthetically derived ECMs provide a viable method of 
biofunctionalising electrospun polymer scaffolds, but that the composition of the synthetically 
derived ECM-polymer hybrid scaffolds influences liver cells. That albumin production is 
significantly altered between SO and SD-ECM conditions, but not N-ECM conditions supports 
this assertion. Gene expression of key hepatic genes was altered on day 5 of SD-ECM 
conditions in every gene tested, whereas SO and N-ECM conditions only influence CYP1A2 
and COL4A1 expression; demonstrating that the composition of the ECM is highly influential 
in tissue engineering. This in turn leads to questions regarding donor-donor variability of 
current decellularization work and its influence upon hepatic behaviour and a need for more 
reproducible hepatic microenvironments that this platform provides. 
The researchers responsible recognise that, while this study forms a robust initial proof of 
principle regarding the exploitation of synthetic biology for scaffold manufacture, and has 
produced a novel hybrid synthetically derived ECM- polymer scaffold with great potential for 
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liver tissue engineering, further work is required to analyse results and increase translatability. 
Vector technologies and synthetic biology present obvious concerns with regards to patient 
safety 30,81, and care should be taken to ensure all bacterial/ viral constructs are removed from 
the ECM layer. Detergent based methods used to strip the ECM of cells can be detrimental to 
the bioscaffold 70,82, disrupting native tissue ultrastructure, decreasing glycosaminoglycan 
(GAG) content and reducing collagen integrity 83,84 as well as disrupting lipid-lipid, lipid-protein 
and protein-protein interactions 85. Care should be taken to optimise this procedure in the 
future. HepG2s provide a convenient method of initial viability testing of the scaffolds, but they 
are derived from a carcinoma and as such criticism of their clinical relevance is well placed. 
Further studies will utilise primary or stem cell derived hepatocytes to combat such criticism. 
Additionally, recognition of the value of further proteomic and functional assays (such as 
ELISAs and Alkaline Phosphatase quantitation) in analysing the function of hepatocytes will 
be vital for expanding this work, however at this time these were deemed unnecessary 
considering the obvious critiques of the use of the HepG2 cell line. Further, the importance of 
ensuring decellularization agents are removed from the constructs should not be 
underestimated, due to their influence upon cells and ECM 21,70. While such criticisms are 
important to consider, this work clearly demonstrates the potential of synthetic biology for the 
design of bespoke ECMs and provides a robust initial platform upon which further, improved 
studies can be built. 
Conclusion 
This study demonstrates a novel method of creating a biologically bespoke hybrid ECM-
polymer scaffold; utilising clinically translatable electrospun scaffold technologies and 
synthetic biology methods both easily modified to fulfil Good Manufacturing Practice (GMP) 
guidelines. In order to achieve this, a sacrificial ECM-producing cell layer was transfected 
using a protein producing fibronectin vector on an electrospun scaffold, biofuctionalizing the 
scaffold with a biologically bespoke ECM. Scaffolds with wild type untransfected cells and no 
initial cell layer at all were used as controls. This sacrificial cell layer was successfully removed 
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with a detergent based method and the hybrid synthetically derived ECM-polymer scaffolds 
seeded with HepG2 liver cells for validation. Results were validated using multiple well 
characterized methods, including mechanical quantitation, Q-PCR and 
immunohistochemistry. The synthetically derived PLA-ECM scaffolds exert biological 
influence upon liver cells, manipulating their microenvironment and resulting in alterations in 
gene expression profile, protein synthesis and cell attachment and survival. Such data 
demonstrates promise as a unique method of creating biologically bespoke ECMs and 
exerting influence upon cell populations both in vivo and in vitro.  
These novel scaffolds exhibit great promise both as an implantable patient treatment for liver 
tissue engineering, for adaptation to other tissues and as a useful tool for development of 3D 
liver cell culture platforms with potential for both in vivo cell analysis and novel pharmaceutical 
research. 
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